Lenalidomide combined with R-GDP in a patient with refractory CD5-positive diffuse large B-cell lymphoma: A promising response and review

CD5-positive (CD5+) diffuse large B-cell lymphoma (DLBCL) is associated with poor survival compared with CD5-negative DLBCL. The clinical characteristics of CD5+ DLBCL are different from both CD5-negative DLBCL and other CD5+ B cell lymphomas. There is currently no promising chemotherapy for CD5+ DL...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Biol Ther
Egile Nagusiak: Zhang, Yaping, Wang, Xinfeng, Liu, Yifei, Sun, Chunfeng, Shi, Wenyu, Huang, Hongming
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Taylor & Francis 2018
Gaiak:
Bedside to Bench Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5989800/
https://ncbi.nlm.nih.gov/pubmed/29611764
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2018.1449609
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak